Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-09-22
2010-02-16
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S184100, C514S002600, C514S012200, C530S399000
Reexamination Certificate
active
07662392
ABSTRACT:
This invention provides methods of improving myocardial function in a subject after ischemic injury comprising administering G-CSF or SDF-1 to the subject.
REFERENCES:
patent: 5008284 (1991-04-01), Grover et al.
patent: 5061620 (1991-10-01), Tsukamoto et al.
patent: 5552381 (1996-09-01), Atkinson
patent: 5599703 (1997-02-01), Davis et al.
patent: 5880090 (1999-03-01), Hammond et al.
patent: 5980887 (1999-11-01), Isner
patent: 6106830 (2000-08-01), Li
patent: 6288103 (2001-09-01), Faull et al.
patent: 2002/0094327 (2002-07-01), Petersen
patent: 2002/0107195 (2002-08-01), Gupta
patent: 2002/0115081 (2002-08-01), Lee et al.
patent: 2003/0054973 (2003-03-01), Anversa
patent: 2003/0171294 (2003-09-01), Hung et al.
patent: 2003/0199464 (2003-10-01), Itescu
patent: 2004/0131585 (2004-07-01), Itescu
patent: 2004/0247564 (2004-12-01), Itescu
patent: 2005/0233992 (2005-10-01), Itescu
patent: 2006/0051334 (2006-03-01), Kornowski
patent: 2006/0057722 (2006-03-01), Kornowski
patent: 2007/0172467 (2007-07-01), Pitrack
patent: 0897980 (1999-02-01), None
patent: WO 98/19712 (1998-05-01), None
patent: WO 98/54210 (1998-12-01), None
patent: WO 99/37751 (1999-07-01), None
patent: WO 99/37779 (1999-07-01), None
patent: WO 09/45775 (1999-09-01), None
patent: WO 99/43839 (1999-09-01), None
patent: WO 99/65507 (1999-12-01), None
patent: WO 00/57922 (2000-10-01), None
patent: WO 01/94420 (2001-12-01), None
patent: WO 02/16416 (2002-02-01), None
patent: WO 0236078 (2002-05-01), None
patent: WO 03/090512 (2003-11-01), None
patent: WO 03047616 (2003-12-01), None
Hattori et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97: 3354-3360, 2001.
Lataillade et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 95: 756-768, 2000.
Itescu et al. (2003) “Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function”Heart Failure Rev. 8: 253-258.
Itescu et al. (2003) “New directions in strategies using cell therapy for heart disease”J. Mol. Med. 81: 288-296.
Noishiki et al. (1999) “Angiogenic growth factor release system for in vivo tissue engineering: a trial of bone marrow transplantation into ischemic mycocardium”J. Artif. Organs 2: 85-91.
Orlic et al. (2001) “Mobilized bone marrow cells repair the infarcted heart, improving function and survival”Proc. Natl. Acad. Sci USA98 (18) :10344-10349.
Yin et al. (1997) “AC 133, A novel marker for human hematopoietic stem and progenitor cells”Blood90 (12) :5002-5012.
Kocher, A.A. et al. (2001) “Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents . . . ,” Nature Medicine 7:430-436.
Beltrami, A. P. et al. (2001) “Evidence that Human cardiac myocytes divide after myocardial infarction,” New England J. Med. 344:1750-1757.
Asahara, T. et al. (1999) “VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells,” The EMBO Journal 18:3964-3972.
Kawamoto, A. et al. (2001) Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia, Circulation 103:634-637.
Murohara, T. et al. (2000) Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization, J. Clin. Invest. 105:1527-1536.
Callard, Robin E. et al. (1994) Cytokin FactsBook, Academic Press.
Lee et al. (1991) J. Biol. Chem. 266(24):16188-16192.
International Search Report issued Oct. 18, 2001 in connection with PCT/US01/18399.
Supplementary Partial European Search Report issued Oct. 25, 2004 in connection with European Patent Application No. 01942041.3.
European Search Report issued Apr. 26, 2004 in connection with E.P. 01942041.
International Search Report issued in connection with PCT/US03/12678, filed Apr. 23, 2002.
Möhle et al. (1998) “The Chemokine Receptor CXCR-4 Is Expressed on CD34+ Hematopoietic Progenitors and Leukemic Cells and Mediates . . . ,” Blood 12: 4523-4530.
Asahara, T. et al. (1999), Circulation Research 85:221-228.
Futamatsu, H. et al. (2003), Cardiovascular Research, 59(1):95-105.
Stenhoff, J. et al. (2004), Biochem. Biophys. Res. Comm., 319(3):871-878.
Gupta, S. et al. (2002), Biochim. Biophys. Acta, 1589(3):247-260.
Placentini, L. et al. (2000), J. Mol. Cell. Cardiol., 32(4):565-567.
Okuno, et al. (2000), Lab. Invest., 80(3):433-440.
Feucht, M. (1997), Am. J. Path., 151(5):-1407-1416.
Asahara, T. et al. (1997), Science, 275:964-967.
Takahashi, T. et al. (1999), Nat. Med., 5:434-438.
Kennedy, M. et al. (1997), Nature, 386:488 493.
Choi, K. et al. (1998), Development, 125:725 732.
Elefanty, A.G. et al. (1997) Blood, 90:1435 1447.
Shi, Q. et al. (1998) Blood, 92:362-367.
Lin, Y. et al. (2000), J. Clin. Invest., 105: 71-77.
Tavian, M. et al. (1996), Blood, 87:67 72.
Jaffredo, T. et al. (1998), Development, 125:4575-4583.
Labastie, M. C. et al. (1998) Blood, 92:3624 3635.
Peichev, M. et al. (2000), Blood, 95:952 958.
Tsai, F.Y. et al. (1994), Nature, 371:221 225.
Bhattachaya, et al. (2000), J. Vasc. Surgery, 32:116-123.
Dale, et al. (1993), Blood, 81:2496-2502.
De Revel, et al. (1994), Blood, (83(12):3795-3799.
Molineaux,.et al. (1990), Blood, 76:2153-2158.
Kajstura, J. et al. (1998) Myocyte proliferation in end-stage cardiac failure in humans, Proc. Natl. Acad. Sci. USA 95:8801-8805.
Kalka, C. et al. (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization, PNAS 97:3422-3427.
U.S. Appl. No. 10/693,480, filed Oct. 23, 2003, Silviu Itescu.
Askari, Arman T. et al. (2003) “Effect of Stromal-Cell-Derived Factor 1 on Stem-Cell Homing and Tissue Regeneration in Ischaemic Cardiomyopathy” The Lancet 362 pp. 697-703.
Behl, C. (2000) “Apoptosis and Alzheimer's Disease” J Neural Transm 107 pp. 1325-1344.
Canbay, Ali et al. (2005) “Apoptosis and Fibrosis in Non-Alcoholic Fatty Liver Disease” Turk J. Gastroenterol 16:1 pp. 1-6.
Moore, M.A.S. et al. (2001) “Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector-Mediated Elevation of Serum Levels of SDF-1, VEGF, and Angiopoietin-1” Annals NY Acad Sci 938 pp. 36-47.
Nagaswa, Takashi (2001) “Role of Chemokine SDF-1/PBSF and Its Receptor CXCR4 in Blood Vessel Development” Ann NY Acad Sci 947 pp. 112-116.
Peled, Amnon et al. (2000) “The Chemokine SDF-1 Activates the Integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ Cells: Role in Transendothelial/Stromal Migration and Engraftment of NOD/SCID Mice” Blood 95:11 pp. 3289-3296.
Petit, Isabelle et al. (2007) “The SDF-1-CXCR4 Signaling Pathway: A Molecular Hub Modulating Neo-Angiogenesis” Trends in Immunology 28:7 pp. 299-307.
Rempel, Sandra A. et al. (2000) “Identification and Localization of the Cytokine SDF1 and Its Receptor, CXC Chemokine Receptor 4, to Regions of Necrosis and Angiogenesis in Human Glioblastoma” Clinical Cancer Research 6 pp. 102-111.
Salcedo, Rosalba et al. (1999) “Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Induce Expression of CXCR4 on Human Endothelial Cells” The American Journal of Pathology 154:4 pp. 1125-1135.
Tachibana, Kazunobu et al. (1998) “The chemokine Receptor CXCR4 is Essential for Vascularization of the Gastrointestinal Tract” Nature 393:11 pp. 591-594.
Tews, D.S. (2002) “Apoptosis and Muscle Fibre Loss in Neuromuscular Disorders” Neuromuscular Disorders 12 pp. 613-622.
Woo, David (1995) “Apoptosis and Loss of Renal Tissue in Polycystic Kidney Diseases” New England Journal of Medicine 333:1 pp. 18-25.
Yamaguchi, Jun-ichi et al., (2003) “Stromal Cell-Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization” Circulation
Bunner Bridget E
Cooper & Dunham LLP
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Use of SDF-1 or G-CSF to improve myocardial function after... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of SDF-1 or G-CSF to improve myocardial function after..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of SDF-1 or G-CSF to improve myocardial function after... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152197